Skip to main content
SAMIL PHARMACEUTICAL CO.,LTD logo

SAMIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000520 ISIN · KR7000520007 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2022-06-15 Major Shareholding Noti…
Country KR South Korea
Listing KO 000520

About SAMIL PHARMACEUTICAL CO.,LTD

https://www.samil-pharm.com/main/EN

Samil Pharmaceutical Co., Ltd. is a company engaged in the research, development, and manufacturing of pharmaceutical products. The company specializes in ophthalmology and also produces a diverse portfolio of drugs for other therapeutic areas, including the central nervous system (CNS), hepatic conditions, and gastrointestinal disorders. Its product range encompasses prescription medicines as well as over-the-counter remedies for common ailments like fever and colds. In addition to developing its own products, Samil Pharmaceutical offers Contract Development and Manufacturing Organization (CDMO) services to global partners. The company emphasizes research and development and collaborates with other leading pharmaceutical firms.

Recent filings

Filing Released Lang Actions
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Samil Pharmaceutical. It details specific changes in share ownership by individuals classified as major shareholders or their relatives, including transaction dates, types (e.g., open market purchase), and updated share counts. This falls under the category of 'Major Shareholding Notification' (MRQ), which tracks changes in significant share ownership levels.
2022-06-15 Korean
타인에대한채무보증결정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory disclosure from Samil Pharmaceutical regarding a 'Decision on Debt Guarantee for Others' (채무보증결정). This is a specific type of corporate event disclosure required by capital market regulations in Korea. Since it does not fit into categories like earnings releases, annual reports, or shareholder meetings, and is a specific regulatory announcement of a material corporate action, it falls under the 'Regulatory Filings' (RNS) category.
2022-05-10 Korean
[기재정정]타인에대한채무보증결정
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from Samil Pharmaceutical regarding a 'Decision on Debt Guarantee for Others' (타인에 대한 채무보증 결정). It details a corporate guarantee provided for a subsidiary's loan for factory construction. This type of disclosure is a standard regulatory requirement in South Korea (DART system) for material corporate events. Since it does not fit into specific categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2022-05-10 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Samil Pharmaceutical. It details specific changes in share ownership by individuals classified as major shareholders or their relatives, including transaction dates, share counts, and percentage changes. This falls under the category of 'Major Shareholding Notification' (MRQ), which tracks changes in significant share ownership levels.
2022-05-10 Korean
분기보고서 (2022.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Samil Pharmaceutical Co., Ltd. for the first quarter of 2022 (ending March 31, 2022). It contains detailed financial information, business operations, management discussion, and governance details, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-05-09 Korean
신탁계약해지결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on the Termination of a Trust Agreement' (신탁계약해지결과보고서) filed by Samil Pharmaceutical Co., Ltd. with the Financial Supervisory Service (FSS) of South Korea. It details the termination of a stock repurchase trust contract with NH Investment & Securities. Since the document reports the completion/termination of a share buyback program (transaction in own shares), it falls under the 'Transaction in Own Shares' category.
2022-05-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.